Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus

Leukemia

Volumn 30, Issue 4, 2016, Pages 854-860

  Leich, E ^a,b   Hoster, E ^c   Wartenberg, M ^a,b   Unterhalt, M ^d   Siebert, R ^e   Koch, K ^f   Klapper, W ^f   Engelhard, M ^g   Puppe, B ^a,b   Horn, H ^h   Staiger, A M ^h   Stuhlmann Laeisz, C ^e   Bernd, H W ⁱ   Feller, A C ⁱ   Hummel, M ^j   Lenze, D ^j   Stein, H ^k   Hartmann, S ^l   Hansmann, M L ^l   Moller P ^m   Hiddemann, W ^d   Dreyling, M ^d   Ott, G ⁿ   Rosenwald, A ^a,b   more..

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Comprehensive Cancer Center Mainfranken ^*  (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h UNIVERSITY OF TÜBINGEN   (Germany)

ⁱ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k Pathodiagnostik Berlin   (Germany)

^l UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^m UNIVERSITY HOSPITAL ULM   (Germany)

ⁿ ROBERT BOSCH HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE; PROTEIN BCL 2;

ADULT; ADVANCED CANCER; ARTICLE; BCL2 GENE; BCL6 GENE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CD10 GENE; CLINICAL FEATURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENE; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN TISSUE; KI67 GENE; MAJOR CLINICAL STUDY; MALE; MUM1 GENE; ONCOGENE MYC; P53 GENE; PRIORITY JOURNAL; SURVIVAL TIME; CHROMOSOME 14; CHROMOSOME 18; CHROMOSOME BREAKAGE; COHORT ANALYSIS; FOLLOW UP; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; PROGNOSIS; SURVIVAL RATE;

CHROMOSOME BREAKAGE; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TRANSLOCATION, GENETIC;

EID: 84955307220     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.330     Document Type: Article

References (30)

1. Harris NL, Swerdlow SH, Jaffe ES, Ott G. Follicular lymphoma. In: Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, et al. (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008, pp 220-226
2. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447-8452
3. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest 2012; 122: 3424-3431
4. Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, et al. Follicular lymphomas with and without translocation t(14; 18) differ in gene expression profiles and genetic alterations. Blood 2009; 114: 826-834
5. Roulland S, Kelly RS, Morgado E, Sungalee S, Solal-Celigny P, Colombat P, et al. t(14; 18) Translocation: a predictive blood biomarker for follicular lymphoma. J Clin Oncol 2014; 32: 1347-1355
6. Sungalee S, Mamessier E, Morgado E, Gregoire E, Brohawn PZ, Morehouse CA, et al. Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression. J Clin Invest 2014; 124: 5337-5351
7. Tellier J, Menard C, Roulland S, Martin N, Monvoisin C, Chasson L, et al. Human t(14; 18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis?. Blood 2014; 123: 3462-3465
8. Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, et al. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov 2012; Jan 2: 47-55
9. Horsman DE, Okamoto I, Ludkovski O, Le N, Harder L, Gesk S, et al. Follicular lymphoma lacking the t(14; 18)(q32; q21): identification of two disease subtypes. Br J Haematol 2003; 120: 424-433
10. Gagyi E, Balogh Z, Bodor C, Timar B, Reiniger L, Deak L, et al. Somatic hypermutation of IGVH genes and aberrant somatic hypermutation in follicular lymphoma without BCL-2 gene rearrangement and expression. Haematologica 2008; 93: 1822-1828
11. Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne RD, et al. MicroRNA profiles of t(14; 18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood 2011; 118: 5550-5558
12. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732
13. Koch K, Hoster E, Unterhalt M, Ott G, Rosenwald A, Hansmann ML, et al. The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease. Hum Pathol 2012; 43: 2274-2281
14. Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006; 107: 1014-1022
15. Engelhard M, Unterhalt M, Hansmann M, Stuschke M. Follicular lymphoma: curability by radiotherapy in limited stage nodal disease?. Updated results of a randomized trial. Ann Oncol 2011; 22(Suppl 4): 90-(abstract 027
16. Haralambieva E, Kleiverda K, Mason DY, Schuuring E, Kluin PM. Detection of three common translocation breakpoints in non-Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections. J Pathol 2002; 198: 163-170
17. Ventura RA, Martin-Subero JI, Jones M, McParland J, Gesk S, Mason DY, et al. FISH analysis for the detection of lymphoma-Associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 2006; 8: 141-151
18. Adam P, Baumann R, Schmidt J, Bettio S, Weisel K, Bonzheim I, et al. The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-?negative? grade 1/2 follicular lymphomas. Hum Pathol 2013; 44: 1817-1826
19. Skinnider BF, Horsman DE, Dupuis B, Gascoyne RD. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 1999; 30: 803-808
20. Vaandrager JW, Schuuring E, Raap T, Philippo K, Kleiverda K, Kluin P. Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes. Genes Chromosomes Cancer 2000; 27: 85-94
21. Guo Y, Karube K, Kawano R, Suzumiya J, Takeshita M, Kikuchi M, et al. Bcl2-negative follicular lymphomas frequently have Bcl6 translocation and/or Bcl6 or p53 expression. Pathol Int 2007; 57: 148-152
22. Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott MM, et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica 2011; 96: 1327-1334
23. Jardin F, Gaulard P, Buchonnet G, Contentin N, Lepretre S, Lenain P, et al. Follicular lymphoma without t(14; 18) and with BCL-6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics. Leukemia 2002; 16: 2309-2317
24. Marafioti T, Copie-Bergman C, Calaminici M, Paterson JC, Shende VH, Liu H, et al. Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups. Histopathology 2013; 62: 860-875
25. Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, et al. Genetics of follicular lymphoma transformation. Cell Rep 2014; 6: 130-140
26. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-2169
27. Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006; 107: 1014-1022
28. Katzenberger T, Kalla J, Leich E, Stocklein H, Hartmann E, Barnickel S, et al. A distinctive subtype of t(14; 18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood 2009; 113: 1053-1061
29. Pham-Ledard A, Cowppli-Bony A, Doussau A, Prochazkova-Carlotti M, Laharanne E, Jouary T, et al. Diagnostic and prognostic value of BCL2 rearrangement in 53 patients with follicular lymphoma presenting as primary skin lesions. Am J Clin Pathol 2015; 143: 362-373
30. Masir N, Campbell LJ, Goff LK, Jones M, Marafioti T, Cordell J, et al. BCL2 protein expression in follicular lymphomas with t(14; 18) chromosomal translocations. Br J Haematol 2009; 144: 716-725